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ABSTRACT
The best unrelated donors (URD) for hematopoietic cell transplantation (HCT) are alleles matched at HLA-A,
-B, -C, and DRB1. Earlier studies mostly used incomplete or lower resolution HLA typing for analysis of trans-
plant outcome. To understand the impact of incomplete HLA characterization, we analyzed 14,797 URD HCT
(1995-2006) using multivariable regression modeling adjusting for factors affecting survival. Of 21 matching co-
horts, we identified 3 groups with significantly different outcomes. Well-matched cases had either no identified
HLA mismatch and informative data at 4 loci or allele matching at HLA-A, -B, and -DRB1 (n5 7477, 50% of the
population). Partially matched pairs had a defined, single-locus mismatch and/or missing HLA data (n 5 4962,
34%).Mismatched cases had$2 allele or antigenmismatches (n5 2358, 16%).Multivariate adjusted 5-year survival
estimates were: well-matched: 54.1 (95% confidence interval), 52.9-55.4), partially matched: 43.7 (42.3-45.2), and
mismatched: 33.4 (32.5-36.5), P\ .001. A better matched donor yielded 10%-11% better 5-year survival. Impor-
tantly, intermediate resolution -A, -B, and -DRB1 alleles matched ‘‘6/6 antigen matched’’ HCT had survival out-
comes within the partially matched cohort. We suggest that these proposed HLA subgroupings be used when
complete HLA typing is not available. This improved categorization of HLA matching status allows adjustment
for donor-recipient HLA compatibility, and can standardize interpretations of prior URDHCT experience.
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Refinements in histocompatibility testing method-
ology have allowed clarification of critical genetic
loci important in regulating alloimmune responses
between donor and recipient surrounding unrelated
donor (URD) hematopoietic cell transplantation
(HCT). As histocompatibility testing has improved,
expandedmatching criteria have been applied to define
the optimal donor and to identify critical loci to match
to achieve superior patient outcome [1-4]. The quality
of donor-recipientmatching canmodify graft rejection
and GVHD as well as protection against neoplastic re-
lapse and the likelihood of long-term survival [5-10].748Numerous important studies have defined the critical
loci for matching to include HLA-A, -B, -C, and
-DRB1 to maximize chances for the patients’ best
long-term outcome [11-18].
The available, searchable donor file, however, is
neither fully typed at all loci nor at allele-level resolu-
tion to allow expeditious selection of the optimal do-
nor. Currently, only approximately 9% of the U.S.
National Marrow Donor Program (NMDP) and
Bone Marrow Donors Worldwide (BMDW) have in-
termediate resolution typing at HLA-A and -B plus
allele typing at -DRB1 available for immediate online
searching. Allele typing has become more readily
Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation 749available andmore widely applied for donor search and
identification over the 20 years of active URD HCT
activity. Nonetheless, in 2006, only 83% of transplants
(not searches) had high-resolution typing at all 4 loci
and 35% of URD transplants had 1 or more missing
or mismatched loci. Importantly, since the founding
of theNMDP and other international donor registries,
many transplants have been performed using donors
selected by incomplete typing with methodologies in-
sufficient to adequately delineate the histocompatibil-
ity existing between donor and recipient. The NMDP
and Center for International Blood and Marrow
Transplant Research (CIBMTR) maintain an exten-
sive database of previous transplants and prospectively
collected long-term outcomes. Improved matching re-
classification that incorporates the completeness and
resolution of previous typings can better utilize this in-
valuable long-term data without attrition because of
incomplete HLA typing. We analyzed the best avail-
able typing compiled from initial pretransplant histo-
compatibility testing, from transplant centers’ later
retrospective high-resolution typing, and from the ret-
rospective NMDP high-resolution Donor-Recipient
Pair project utilizing stored pretransplant blood sam-
ples from the NMDP Research Sample Repository
[10,14] in conjunction with clinical outcomes data in
14,797 URD transplants performed between 1995
and 2006.
To better classify the match grades of prior trans-
plants and thereby guide retrospective analyses of their
outcome where HLA typing may be incomplete or at
lower resolution, we need to understand the potential
impact of that unknown HLA data on outcome in any
retrospective analyses performed. We classified the
number of HLA loci tested (or unknown) and the typ-
ing resolution (antigen level equivalent to intermediate
resolution DNA typing or allele level, high-resolution
DNA-based typing) based on a previously described
standard definition [19] for all transplants and exam-
ined both matching and clinical criteria relevant to
predict their outcome. Multivariate modeling was
then used to describe clusters of matching subsets
with similar outcome and thereby define the outcome
for HCT patients whose HLA-match grade was pre-
dicted by the regression models. We propose a new
classification of HLA-matching into 3 groups to be
used for all retrospective analyses of URD HCT. We
urge the transplant community to replace the widely
used, but inadequate, classification of ‘‘MUD’’
(matched URD transplantation) in all future analyses
where allele-level typing is incomplete.
METHODS
All patients whose URD HCT was facilitated by
the NMDP or reported to the CIBMTR between
1995 and 2006 were eligible to be included in the study(n 5 15,867). Surviving patients who did not provide
signed, informed consent to allow analysis of their
clinical data were excluded. All surviving recipients
included in this analysis were retrospectively contacted
and provided informed consent for participation in the
NMDP research program. Informed consent was
waived by the NMDP institutional review board for
all deceased recipients. To adjust for the potential
bias introduced by exclusion of nonconsenting surviv-
ing patients, a corrective action plan (CAP)-modeling
process randomly excluded the same percentage of
deceased patients using a biased coin randomization
with exclusion probabilities based on characteristics
associated with not providing consent for use of the
data in survivors. This CAP modeling left 14,887
(93.9%) cases to include a broad assessment of HCT
recipients. Thirty-five cases were deleted because of
rare diagnoses (breast cancer, other diseases, or an in-
herited abnormality of platelets), 7 with missing fol-
low-up data on their first transplant, 25 missing
patient race, and 23 in the HLA groups where there
were fewer than 20 cases in the group. HLA data was
compiled from the ‘‘best available typing’’ data table
in the NMDP/CIBMTR database using either trans-
plant center-reported HLA-typing available prior to
transplant, retrospectively submitted refined or higher
resolution histocompatibility typing plus data derived
from the NMDP-sponsored Donor-Recipient Pair
Project, which retrospectively performed multiple
locus allele level typing for 5708 patients within the
data file.
Clinical outcome data was extracted from the
NMDP/CIBMTR outcomes database. Survival was
modeled using a Cox multivariable regression with
the following potentially relevant factors: patient age,
donor age, disease, and stage, Karnofsky performance
score, patient CMV serology, cell source (bone mar-
row versus filgrastim-primed peripheral blood
[PBSC]), first or subsequent transplant, conditioning
regimen intensity, patient and donor race, GVHD
prophylaxis, and year of transplant. The model was
stratified on the 21 defined HLA-matching groups
derived from the patient population grouped by
number of loci tested (from HLA-A, -B, -C, and
-DRB1), level of resolution (intermediate/low or
high) at each locus, and extent of mismatch (Table 1).
HLA-DQ and -DPwere not included, as previous anal-
yses had shown them of lesser importance [10,18]. The
final Cox model stratified on the HLA matching group
was used to estimate the baseline survival function and
95% confidence interval (CI). One-year survival
estimates were based on Breslow’s estimator and
a log-log transform CI [20].
Groups were clustered based upon similarity of
these regression model-defined 1-year survival esti-
mates and the presence of 0, 1, or$2 identifiedmissing
or mismatched loci.
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A. HLA Matching Groups No. (%)
HLA Group 14,797
1 Matched 8/8 at high-res HLA-A, -B, and -DRB1 and low-res at HLA-C 428 (3)
2 Matched 8/8 at high-res HLA-A, -B, -C, and -DRB1 5517 (37)
3 Matched 8/8 at low-res HLA-A, -B, and -C and high-res at HLA-DRB1 1408 (9)
4 Matched 6/6 at high-res HLA-A, -B, and -DRB1 (HLA-C unknown) 124 (1)
5 Single-allele MM (7/8) at high-res HLA-A, -B, -C, and -DRB1 1003 (7)
6 Single-allele MM (5/6) at high-res HLA-A, -B and -DRB1 (HLA-C unknown) 22 (\1)
7 Single-antigen MM (7/8) at high-res HLA-A, -B, -C, and -DRB1 1509 (10)
8 Single MM (7/8) at high-res HLA-A, -B, and -DRB1 and low-res at HLA-C 177 (1)
9 Matched 6/6 at low-res HLA-A and -B and high-res at HLA-DRB1 (HLA-C unknown) 1742 (12)
10 Matched 8/8 at low-res HLA-A, -B, -C, and -DRB1 79 (1)
11 Single-MM (7/8) at low-res HLA-A, -B, and -C and high-res at HLA-DRB1 430 (3)
12 Two or more allele MM (\7/8) at high-res HLA-A, -B, -C, and -DRB1 185 (1)
13 Matched (6/6) at low-res HLA-A, -B, and -DRB1 (HLA-C unknown) 87 (1)
14 Single-MM (5/6) at low-res HLA-A and -B and high-res at HLA-DRB1 (HLA-C unknown) 545 (4)
15 Two or more MM with 1 antigen MM (\7/8) at high-res HLA-A, -B, -C, and -DRB1 650 (4)
16 Two or more MM with 2 or more antigen MM (\7/8) at high-res HLA-A, -B, -C, and -DRB1 650 (4)
17 Single-antigen MM (5/6) at high-res HLA-A, -B, and -DRB1 (HLA-C unknown) 23 (\1)
18 Two or more MM (\7/8) at low-res HLA-A, -B, -C, and high-res at HLA-DRB1 104 (1)
19 Single-MM (7/8) at low-res HLA-A, -B, and -C and -DRB1 24 (\1)
20 Two or more MM (\7/8) at high-res HLA-A, -B, and -DRB1 and low-res at HLA-C 61 (\1)
21 Two or more MM (\5/6) at low-res HLA-A and -B and high-res at HLA-DRB1 (HLA-C unknown) 29 (\1)
B. Patient Characteristics No. Eval No. (%)
Number of patients 14,797
Number of centers 166
Age, median (range), years 14,796 37 (\1-79)
Age at transplant 14,796
\ 18 years 3155 (21)
18-30 years 2688 (18)
31-45 years 3929 (27)
Over 45 years 5024 (34)
Male sex 14,796 8691 (59)
Karnofsky prior to transplant $90 13,671 9437 (69)
Recipient CMV status 14,619
Negative 6891 (47)
Positive 7728 (53)
Recipient race 14,797
White 12,854 (87)
African American 837 (6)
Hispanic 477 (3)
Asian/Pacific Islander 294 (2)
Other 335 (2)
Graft type 14,797
Bone marrow 9075 (61)
PBSC 5722 (39)
Conditioning regimen* 14,797
Traditional myeloablative 9166 (62)
Nontraditional myeloablative 2607 (17)
Reduced intensity 1433 (10)
Nonmyeloablative 1180 (8)
Other 411 (3)
Disease at transplant† 14,797
AML early 1225 (8)
AML intermediate 1245 (8)
AML late 1687 (11)
AML unknown 125 (1)
ALL early 713 (5)
ALL intermediate 1118 (8)
ALL late 525 (4)
ALL unknown 58 (\1)
Other leukemia 675 (5)
CML early 1511 (10)
(Continued )
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B. Patient Characteristics No. Eval No. (%)
Disease at transplant† (continued)
CML intermediate 708 (5)
CML late 142 (1)
CML unknown 101 (1)
MDS early 339 (2)
MDS late 654 (4)
MDS unknown 699 (5)
Non-Hodgkin lymphoma (NHL) 1372 (9)
Hodgkin lymphoma 353 (2)
Myeloma, plasma cell disorders 311 (2)
Other malignancies 54 (\1)
Severe aplastic anemia (SAA) 600 (4)
Inherited abnormalities of erythrocytes 28 (\1)
SCID and other immune system disorders 229 (2)
Inherited disorder of metabolism 215 (1)
Histiocytic disorders 110 (1)
Disease status at transplant‡ 14,797
Early 3792 (26)
Intermediate 7413 (50)
Late 3010 (20)
Other 582 (4)
First transplant 14,797
Yes 12,563 (85)
No 2234 (15)
GVHD prophylaxis 14,797
Tac or CSA ± MTX ± MMF ± other 10,122 (68)
Tac or CSA ± other (no MTX) 2046 (14)
MMF or MTX ± other (No Tac or CSA) 84 (1)
T cell depletion 1818 (12)
Other 727 (5)
Donor/recipient sex match 13,983
Male/male 5502 (39)
Male/female 3271 (24)
Female/male 2710 (19)
Female/female 2500 (18)
Donor/recipient CMV serostatus 14,797
Negative/negative 4687 (32)
Negative/positive 4582 (31)
Positive/negative 2131 (14)
Positive/positive 3056 (21)
Unknown 341 (2)
Donor age, median (range), years 13,983 35 (18-61)
Year of transplant 14,797
1995-1998 3503 (24)
1999-2002 4450 (30)
2003-2006 6844 (46)
Median follow-up of survivors (range), months 5428 37 (1-140)
PBSC indicates peripheral blood stem cells; MTX, methotrexate; MMF, mycophenylate mofetil; Tac, tacrolimus; MM, mismatched.
*Traditional myeloablative5 total body irradiation (TBI) .800 cGy or cyclophosphamide.100 mg/kg plus busulfan or etoposide. Nontradi-
tionalmyeloablative5 busulfan.9mg/kg ormelphalan.150mg/kg6 other (not above). Reduced intensity5 busulfan#9mg/kg ormelphalan
#150 mg/kg or cyclophosphamide\100 mg/kg 6 fludarabine or other not above. Nonmyeloablative 5 TBI 200 cGy and/or fludarabine 6
other not above.
†Early5 acute leukemia CR1, CML CP1 or MDS RA or IPSS-1. Intermediate 5 acute leukemia CR 2-3, MDS RAEB or IPSS-2-3, CML ac-
celerated or CP2. Late 5 leukemia in relapse, CML blast phase or MDS RAEB-T or IPSS-4.
‡Early as above. Intermediate includes NHL, HL, Myeloma, other/unknown malignancies. Late as above. Other 5 other and nonmalignant
disorders.PATIENTS
The patient demographics including patient, dis-
ease, and transplant technique characteristics poten-
tially affecting transplant outcomes are shown inTable 1B. Table 2 shows the estimated 1-year survival
for an example, baseline patient (age\18 years, acute
myetogenous leukemia (AML) early disease,Karnofsky
performance status (KPS) 90-100, cytomegalovirus
752 D. Weisdorf et al.(CMV) negative, marrow cell source, 1st HCT, mye-
loablative conditioning, tacrolimus/methotrexate
graft-versus-host disease (GVHD) prophylaxis, per-
formed in 1995-1998) stratified on HLA matching
group. Figure 1 depicts the baseline survival curves (ad-
justed as if for this example patient) for the HLA sub-
groups. Table 3 shows the relevant clinical factors
modifying survival based on the final Cox model.
As shown, the 1-year survival estimates derived
from the multivariable regression identified 3 clusters
of HLA subgroups defined by available high resolu-
tion data, number of loci typed, and absence of
known mismatches (Table 2 and Figure 1). The
best group, identified as ‘‘well-matched,’’ had 1-year
survival estimates from 62.0% to 68.3%, and in-
cluded 7477 patients, 50% of the whole population.
The intermediate group, ‘‘partially matched,’’ weremissing either high-resolution or HLA-C data or
had a defined single-locus mismatch. These included
4962, 34% of the population, and had estimated 1-
year survival from 55.0% to 61.3%. The ‘‘mis-
matched’’ group with the poorest outcome included
those with 2 or more known mismatches or missing
data. This group included 2358, 16% of the popula-
tion, and estimated 1-year survival between 34.4%
and 56.7%. Although 1-year survival for group 12
overlaps in outcome with group 11, the 2 mismatched
alleles in this group suggest it is more appropriately
classified with the mismatched cohort. As shown in
Figure 1, these survival estimates defined 3 HLA sub-
group clusters with survival at 1 year for a patient
with an average set of covariates estimated as 67.7
(95% CI 66.6-68.9) for the well-matched, 56.1
(95% CI 54.6-57.5) for the partially matched, andTable 2. Survival after URD HCT by HLA Match Classifications
1-Year Survival
HLA Group No. of HLA loci matched and resolution Survival SE 95% CI
Well matched
1 8/8 high-res A, B, and DRB1, low-res at C 68.3% 2.5% 65.5% 70.9%
2 8/8 high-res A, B, C, and DRB1 67.2% 1.6% 65.5% 68.8%
3 8/8 low-res A, B, and C, high-res at DRB1 65.5% 1.9% 63.4% 67.4%
4 6/6 high-res A, B, and DRB1 (C unknown) 62.0% 4.1% 57.6% 66.2%
Partially matched
5 1 allele MM at high-res A, B, C, and DRB1 61.3% 2.2% 59.0% 63.8%
6 1 allele MM high-res A, B, and DRB1
(C unknown)
59.7% 8.9% 44.5% 68.4%
7 1 antigen MM high-res A, B, C, and DRB1 59.7% 2.0% 57.4% 61.8%
8 1 MM high-res A, B, and DRB1, low-res C 59.6% 3.8% 55.3% 63.8%
9 6/6 low-res A and B, high-res DRB1
(C unknown)
59.2% 1.9% 57.1% 61.1%
10 8/8 low-res A, B, C, and DRB1 60.2% 6.7% 52.7% 66.8%
11 1 MM low-res A, B, and C, high-res DRB1 55.0% 2.9% 51.9% 58.0%
Mismatched
12 21 allele MM high-res A, B, C, and DRB1 56.7% 3.6% 52.6% 60.4%
13 6/6 low-res A, B, and DRB1 (C unknown) 49.0% 5.1% 43.5% 54.3%
14 1 MM low-res A and B, high-res DRB1
(C unknown)
51.8% 2.6% 49.1% 54.5%
15 21MMwith 1 antigenMM (\7/8) high-res
A, B, C, and DRB1
51.6% 2.6% 48.9% 54.1%
16 21 antigen MM high-res A, B, C, and
DRB1
50.1% 2.6% 47.2% 52.8%
17 1 MM high-res A, B, and DRB1
(C unknown)
48.5% 8.7% 39.1% 57.4%
18 21 MM low-res A, B, and C, high-res
DRB1
45.2% 4.9% 39.9% 50.3%
19 1 MM low-res A, B, C, and DRB1 45.1% 10.7% 33.8% 56.2%
20 21MMhigh-resA, B, andDRB1, low-resC 40.7% 6.5% 33.7% 47.5%
21 21 MM low-res A and B, high-res DRB1
(C unknown)
34.4% 8.7% 25.5% 43.5%
High-res indicates high resolution, allele level typing; Low-res, low/intermediate (antigen level) resolution; MM, mismatch; CI, confidence
interval.
Shown for each donor:recipient matching cohort are the adjusted 1-year survival estimates6 SE for an example patient assumed to be receiving
a first transplant who is a CMV negative,\18-year-old patient with a 25-year-old donor. Groups are numbered as in Table 1A. The example
patient is assumed to be White with a KPS of 90-100, transplanted during 2003-2006 using myeloablative conditioning and tacrolimus plus
methotrexate as GVHD prophylaxis.
Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation 75333.4 (95% CI 32.5-36.5) for the mismatched URD
HCT recipients.
IMPACT OF HLA-MATCHING COHORTS ON SURVIVAL
Identifying these 3 HLA subgroup clusters we
sought to estimate the survival for hypothetical
patients with these 3 match grades after adjusting
for the important and statistically significant clinical
risk factors including patient age, race, KPS, year of
transplant, conditioning intensity, and GVHD
prophylaxis. In the figures following (Figures 2 and
3), we illustrate 1-year (Figure 2) and 5-year
(Figure 3) survival for a first transplant, CMV sero-
negative patient with a 25-year-old marrow donor
of match grade shown. The patient examples are
assumed to be White, with a KPS of 90% to 100%,
transplanted in 2003-2006 using tacrolimus plus
short course methotrexate as GVHD prophylaxis.
The example transplant recipients all received
myeloablative conditioning intensity except the 55-
year-old MDS patients, who are assumed to have
received a reduced-intensity conditioning (RIC)
regimen.
As shown, for all six example patients (panels A-F,
Figures 2 and 3), the defined matched grade group-
ings identify clearly distinct survival at 1 year and 5
years for all patient cohorts including those with
either early or late disease stage, who were either
Figure 1. Estimated 1-year survival for a first transplant, under 18
years old, CMV-negative patient with a 25-year-old donor. The pa-
tient is assumed to be White with a KPS of 90-100, transplanted in
2003-2006 usingmyeloablative conditioning and tacrolimus/metho-
trexate as GVHD prophylaxis. The 21 groups cluster (per Table 2)
as: well matched (thin/blue lines); partially matched (thick/red lines);
andmismatched (medium/green lines). Right panel in color for web-
site display.older or younger. HLA-matching groups resulted in
approximately 10% to 11% decrements in 5-year
survival between the well-matched, partially matched,
and mismatched groups for each modeled patient
cohort.
Greater differences were recognized within the
first year posttransplant, suggesting that the impact
of HLA-matching has a more profound effect on
early posttransplant mortality presumptively because
of graft failure, GVHD, and infection, than on later
posttransplant (5 year outcomes), which may be
dominated by both relapse and chronic GVHD
(cGVHD) and thus possibly less affected by HLA
disparity.
Examining the HLA-matching groups in detail
(Table 2) identifies best outcomes associated with no
recognized mismatch and informative, although not
necessarily high-resolution data at all 4 loci (HLA-A,
-B, -C, and -DRB1) or with allele matching at HLA-A,
-B, and -DRB1. In group 4, high-resolution typing at
HLA-A, -B, and -DRB1 overcomes the potentially un-
recognized mismatches at the untested HLA-C locus
because of strong linkage disequilibrium with HLA-
C in high-resolution HLA-B matched pairs. Although
outcomes overlap with group 5, the lack of any defined
mismatch suggests this subgroup should be in the well-
matched group. Well-matched transplants, therefore,
are characterized by informative data at the HLA-A,
-B, -C and -DRB1 loci and no defined mismatch,
even if high-resolution typing is not available at Class
I loci (groups 1-4).
In contrast, the partially matched group (Table 2,
groups 5-11) includes defined, single-locus mis-
matches at any of the 4 loci using either high-resolution
or low/intermediate-resolution (allele or antigen) typ-
ing. Most surprisingly, the group traditionally called
‘‘matched’’ and referred to in the casual parlance as
‘‘MUD’’ (matched URD) is group 9. These are
matched at low/intermediate resolution for HLA-A
and -B and high resolution for -DRB1 with unknown
data at HLA-C. This largest (in the partially matched)
subgroup (1742 patients, 12%of thewhole population)
has projected 1-year survival, 9% inferior to the well-
matched group. This clearly indicates that the widely
used term ‘‘6 of 6 matched URD’’ is both insufficiently
precise and a definitive misnomer. In this group, many
unrecognizedmismatches exist that contradict that this
MUD group is ‘‘matched’’ and explaining the poorer
outcomes in this group. Similarly, 8 of 8 low-resolution
matching (group 10), although uncommon, also leads
to worsened survival at 1 year. This emphasizes the
importance of examining all 4 loci and the level of
resolution to understand the impact of matching on
outcome.
The third, mismatched cohort (Table 2, groups
12-21) has greater heterogeneity and includes either
mismatch or missing information at 2 or more loci in
754 D. Weisdorf et al.Table 3. Risk Factors Adjusted for in Estimating 1-Year Survival
Factor RR 95% CI P-value
Patient age
\18 1.00
18-30 1.33 1.24 1.44 \.0001
30-45 1.48 1.38 1.60 \.0001
.45 1.78 1.65 1.92 \.0001
Disease/stage
AML early 1.00
AML intermediate 0.95 0.86 1.05 .3097
AML late 1.49 1.37 1.62 \.0001
AML unknown 1.43 1.13 1.81 .0028
ALL early 0.82 0.73 0.93 .0015
ALL intermediate 1.14 1.03 1.26 .0140
ALL late 1.86 1.66 2.08 \.0001
ALL unknown 1.37 0.97 1.94 .0773
CML early 0.62 0.57 0.69 \.0001
CML intermediate 0.87 0.78 0.98 .0187
CML late 1.37 1.13 1.66 .0014
CML unknown 0.95 0.74 1.22 .6995
MDS early 0.88 0.76 1.03 .1192
MDS late 1.13 1.01 1.26 .0387
MDS unknown 1.01 0.90 1.14 .8359
NHL 1.14 1.04 1.26 .0050
Hodgkin’s lymphoma 1.04 0.88 1.30 .6238
Myeloma plasma cell disorder 1.09 0.93 1.27 .2792
Other malignancies 2.01 1.48 2.73 \.0000
SAA 0.91 0.80 1.05 .1950
Inherited abnormalities of erythrocytes 0.41 0.18 0.84 .0276
SCID and immune system disorders 0.67 0.53 0.87 .0007
Inherited disorders of metabolism 0.70 0.57 0.86 .0010
Histiocytic disorders 0.95 0.71 1.27 .7411
Karnofsky
90-100 1.00
\90 1.38 1.32 1.46 \.0001
Missing 1.02 0.94 1.11 .6279
Patient CMV
Negative 1.00
Positive 1.15 1.10 1.20 \.0001
Cell Source
Marrow 1.00
PBSC 1.00 0.94 1.06 1.00
First Transplant
Yes 1.00
No 1.28 1.19 1.37 \.0001
Conditioning
Traditional myeloablative 1.00
Nontraditional myeloablative 0.92 0.85 1.01 .0646
Reduced intensity 0.85 0.80 0.91 \.0001
Nonmyeloablative 0.73 0.66 0.80 \.0001
Other 0.86 0.75 0.99 .0419
Race
White 1
African American 1.28 1.17 1.40 \.0001
Hispanic 1.12 1.00 1.40 .0495
Asian/Pacific Island 1.03 0.88 1.20 .7439
Other 0.93 0.80 1.08 .3459
Donor age
Relative risk/change in year 1.00 1.00 1.01 .0005
GVHD prophylaxis
Tacrolimus ± MTX ± MMF ± Steroids ± Other 1.00
Tacrolimus ± other 1.03 0.91 1.17 .6312
CSA 1 MTX ± other 1.01 0.95 1.07 .8057
CSA ± other (no MTX) 1.22 1.13 1.33 \.0001
MMF ± other 1.07 0.71 1.62 .7394
(Continued )
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Factor RR 95% CI P-value
MTX ± other (no CSA) 1.65 1.19 2.29 0.0027
T cell depletion 1.14 1.06 1.23 0.0006
Other 1.43 1.23 1.67 \0.0001
Year of HCT
1995-1998 1.00
1999-2002 0.87 0.82 0.92 \.0001
2003-2006 0.74 0.69 0.80 \.0001
CSA indicates cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate.
Shown are the relative risks (RR), 95% confidence interval (CI), and P value from Cox regression modeling of 1-year survival.
Figure 2.Estimated survival for different patients undergoing a first transplant. Patients are all assumed to be CMVnegative,White, with a KPS
of 90-100, transplanted in 2003-2006 receiving tacrolimus/methotrexate as GVHD prophylaxis and a 25-year-old donor. All transplants are
assumed myeloablative except the 55-year-old late MDS patient who was assumed to have a reduced-intensity transplant. Patients’ age, disease,
and disease stage are as shown in each panel.
756 D. Weisdorf et al.Figure 3. Estimated 5-year survival for different patients undergoing a first transplant. Patients are assumed to be CMV negative, White, with
a KPS of 90-100, transplanted in 2003-2006 receiving tacrolimus/methotrexate as GVHD prophylaxis and a 25-year-old donor. All transplants
are assumed myeloablative except the 55-year-old late MDS patient who was assumed to have a reduced-intensity transplant. Patients’ age, dis-
ease, and disease stage are as shown in each panel.all groups. Additionally, either single low-resolution
mismatch (group 14) or high-resolution mismatch
(groups 17 and 21) with unknown C typing yields
poorer survival as does 6 of 6 low resolution matching
with unknown data at HLA-C (group 13).
DISCUSSION
These data strongly emphasize that classification
and analysis of previous URDHCT is best performed
and most informed when it considers data at the 4
most critical loci, HLA-A, -B, -C, and -DRB1. In cur-rent donor selection, this has become widely adopted.
During 2006, 83% of transplants performed had high-
resolution typing at all 4 loci. Of these transplants,
only 65% were well matched, whereas 26% were par-
tially matched and 6% mismatched using this new
classification schema (CIBMTR/NMDP data, unpub-
lished). This new classification suggests that in retro-
spective analyses, pairs with no defined mismatch
and informative data at all 4 loci can be analyzed to-
gether as the best donor:recipient pairs for transplan-
tation among previous typed transplants. This new
schema does not imply that the subgroups within the
3 cohorts are equivalent or should be used for current
Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation 757donor selection where informative, allele-level typing
at all 4 loci is preferred.
Recognizing these 3 defined HLA-matching
groups, the CIBMTR and NMDP propose that all
subsequent retrospective analyses of URD HCT in-
clude the available informative data at all these 4
loci. We also propose that these 3 match grade clas-
sifications be used in all retrospective analyses of out-
come. Reanalysis of data sets previously published
that defined MUD by the older, and insufficiently
precise term ‘‘6 of 6 matching’’ with low/intermediate
resolution at Class I and missing data on HLA-C
combines nearly 25% of patients in the intermediate,
partially matched group with the other, truly well-
matched cohort, and thus confounds interpretation
of all older URD transplant reports. A previous
NMDP analysis identified allele level mismatches in
50% of ‘‘6/6 antigen matched’’ pairs; 31% were mis-
matched at HLA-C [14]. Earlier clinical reports,
therefore, may have obscured differences in outcomes
that might have been attributable to incomplete HLA
matching.
We urge the transplant community to adopt this
schema for all retrospective and comparative analyses,
and we anticipate its validation in future studies of al-
ternative donor transplantation including umbilical
cord blood and RIC cohorts. Although allele-level
precision is, of course, preferred and should be uti-
lized for current donor selection [10,18], this classifi-
cation maximizes the use of available information to
better define interpretations of prior experience and
to inform physicians and their patients for future de-
cision making about the application and outcomes of
URD HCT.
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